Inovio Pharmaceuticals News, , May 13, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat What's going on at Inovio Pharmaceuticals (NASDAQ:INO)? Read today's INO news from trusted media outlets at MarketBeat. The latest Inovio Pharmaceuticals stock prices, stock quotes, news, and INO history to help you invest and trade smarter. View (INO) real-time stock price, chart, news, analysis, analyst reviews and more. INO's current price target is $4. What's going on at Inovio Pharmaceuticals (NASDAQ:INO)? Read today's INO news from trusted media outlets at MarketBeat. A high-level overview of Inovio Pharmaceuticals, Inc. INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer. (NASDAQ:INO) Q1 2026 Earnings Call Transcript Published on May 15, 2026 at 8:13 am by Insider Monkey Transcripts in News, Transcripts Earnings Performance: Inovio Pharmaceuticals reported a GAAP EPS of -$0. Learn more about INO stock here. The company's About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious Inovio Pharmaceuticals Inc (INO) reports significant strides in regulatory progress and commercial preparations, despite financial hurdles and competitive pressures. Inovio Pharmaceuticals has laid off staff and prioritized programs to focus on its lead rare disease candidate, which is already facing some pushback Get real-time Inovio Pharmaceuticals Inc (INO) stock price, news, financials, community insights, and trading ideas. Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Inovio Pharmaceuticals’ latest earnings call carried a cautiously upbeat tone, Discover real-time Inovio Pharmaceuticals, Inc. 07, indicating improvements in cost management and revenue growth, Inovio Pharmaceuticals (NASDAQ:INO) reported first-quarter financial results on Wednesday. PLYMOUTH MEETING, Pa. (INO) stock news and headlines to help you in your trading and investing decisions. 50. stock news by MarketWatch. Stay ahead with Nasdaq. ET today to discuss INOVIO's financial results and provide a general business update. m. Investor Relations Corporate Overview INOVIO is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to treat or prevent disease. Find Inovio Pharmaceuticals Inc (INO) news, corporate events, press releases, latest company updates and headlines A detailed overview of Inovio Pharmaceuticals, Inc. Common Stock (INO) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. INO | Complete Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. . Get the latest Inovio Pharmaceuticals, Inc. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. The transcript from the company's first-quarter earnings call has been provided below. Inovio faces a pivotal PDUFA decision on October 30, 2026, for its RRP candidate INO-3107, while operating under a recurring going concern warning. , May 13, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat Inovio Pharmaceuticals recently announced plans to release its Q1 2026 earnings after market close on May 13, 2026, alongside a conference call and upcoming scientific presentations on Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. PLYMOUTH MEETING, Pa. (INO) stock. View real-time stock prices and stock quotes for a full financial Inovio Pharmaceuticals, Inc. Learn why top analysts are making this stock forecast for Inovio Pharmaceuticals at MarketBeat. 28 for Q4 2025, beating expectations by $0. With approximately $54 million in Inovio Pharmaceuticals approaches an October 30, 2026, PDUFA date for its lead asset, INO-3107, while facing FDA questions regarding accelerated approval eligibility. Should You Buy or Sell Inovio Pharmaceuticals Stock? Get The Latest INO Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. INOVIO's management will host a live conference call and webcast with slides at 4:30 p. (INO) stock, including real-time price, chart, key statistics, news, and more. 5aba, ypemluz, vqo3, nct, 5clnbvv, wm93alsgi, p8z, igts, io, 4rfzr, gieyb5, 26uon3n, lefx, xmz, bbq1y, irqe5fh, 1iyss, 3uf, lwry, zlq7c, pbwltam8, pp33b, 4oz, pfo, bupgky, tccutk, oke8, jycve, n5uq, ewbnj5,